An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation

Fu,You; Tian,Guocai; Li,Jiang; Zhang,Zhiyuan; Xu,Ke

doi:10.3892/ijmm.2020.4680

An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation

Authors:
- You Fu
- Guocai Tian
- Jiang Li
- Zhiyuan Zhang
- Ke Xu
View Affiliations

Affiliations: Shanghai Key Laboratory of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China
Published online on: July 22, 2020 https://doi.org/10.3892/ijmm.2020.4680
Pages: 1501-1513
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The lack of reliable animal models to assess the safety and efficacy of drugs and to explore the underlying molecular mechanisms is one of the most severe impediments in head and neck squamous cell carcinoma (HNSCC) tumor immunology research. The majority of xenograft tumor models established using immunodeficient mice neglect the effects of T cells. To date, to the best of our knowledge, there is no syngeneic tumor model available that reflects the immune microenvironmental features of HNSCC tumors. To solve this issue, the present study used 4‑nitroquinoline‑1‑oxide (4‑NQO) to induce squamous cell carcinoma in C57BL/6 mice. Three HNSCC cell lines were then established, and one of these, termed JC1, was selected for further analysis due to its enhanced proliferative ability and tumorigenicity in immunodeficient nude mice. However, none of the 3 cell lines could form tumors in immunocompetent mice. Due to the different tumorigenicities in nude and C57BL/6 mice, the immune system may play an important role in inoculated JC1 tumor progression. Chemical induction was used to establish the tumorigenicity‑enhanced cell line, JC1‑2, which can form syngeneic tumors in immunocompetent C57BL/6 mice. Next‑generation sequencing (NGS) was used to perform the immunogenomic and transcriptomic characterization of the JC1‑2 cells. Splenocytes were isolated from C57BL/6 mice and co‑cultured with JC1‑2 cells to verify the responsiveness of the interferon (IFN)‑γ pathway in the JC1‑2 cell line. Unlike the majority of syngeneic mouse tumors, the JC1‑2‑formed tumors resembled ‘inflamed tumors’ due to the abundancy of immune cells in the tumor microenvironment. Moreover, more intense immune responses were observed in the orthotopic mouse model than in the heterotopic model. Thus, this model could be used to delineate the interactions between HNSCC and lymphocytes, and to validate novel immunotherapy targets.

View Figures

View References

1	De Moerlooze L, Spencer-Dene B, Revest JM, Hajihosseini M, Rosewell I and Dickson C: An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development. 127:483–492. 2000.PubMed/NCBI
2	Kang H, Kiess A and Chung CH: Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 12:11–26. 2015. View Article : Google Scholar
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Beenken A and Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov. 8:235–253. 2009. View Article : Google Scholar : PubMed/NCBI
5	Rothschild U, Muller L, Lechner A, Schlösser HA, Beutner D, Läubli H, Zippelius A and Rothschild SI: Immunotherapy in head and neck cancer-scientific rationale, current treatment options and future directions. Swiss Med Wkly. 148:w146252018.
6	Gould SE, Junttila MR and de Sauvage FJ: Translational value of mouse models in oncology drug development. Nat Med. 21:431–439. 2015. View Article : Google Scholar : PubMed/NCBI
7	de Visscher SA, Witjes MJ, van der Vegt B, de Bruijn HS, van der Ploegvan den Heuvel A, Amelink A, Sterenborg HJ, Roodenburg JL and Robinson DJ: Localization of liposomal mTHPC formulations within normal epithelium, dysplastic tissue, and carcinoma of oral epithelium in the 4NQO-carcinogenesis rat model. Lasers Surg Med. 45:668–678. 2013. View Article : Google Scholar : PubMed/NCBI
8	Miki K, Orita Y, Gion Y, Takao S, Ohno K, Takeuchi M, Ito T, Minoura A, Tachibana T, Marunaka H, et al: Tumor-associated macrophages in the development of 4-nitro-quinoline-1-oxide-induced tongue squamous cell carcinoma in a mouse model. Oncology. 93:204–212. 2017. View Article : Google Scholar
9	Young MR: Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer. J Immunother. 31:148–156. 2008. View Article : Google Scholar : PubMed/NCBI
10	Tseng SH, Yang CC, Yu EH, Chang C, Lee YS, Liu CJ, Chang KW and Lin SC: K14-EGFP-miR-31 transgenic mice have high susceptibility to chemical-induced squamous cell tumorigenesis that is associating with Ku80 repression. Int J Cancer. 136:1263–1275. 2015. View Article : Google Scholar
11	Miki K, Orita Y, Gion Y, Takao S, Ohno K, Takeuchi M, Ito T, Hanakawa H, Tachibana T, Marunaka H, et al: Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma. Cancer Immunol Immunother. 65:1401–1410. 2016. View Article : Google Scholar : PubMed/NCBI
12	Yang Y: Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest. 125:3335–3337. 2015. View Article : Google Scholar : PubMed/NCBI
13	Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, et al: Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 543:728–732. 2017. View Article : Google Scholar : PubMed/NCBI
14	Olson B, Li Y, Lin Y, Liu ET and Patnaik A: Mouse models for cancer immunotherapy research. Cancer Discov. 8:1358–1365. 2018. View Article : Google Scholar : PubMed/NCBI
15	Efremova M, Rieder D, Klepsch V, Charoentong P, Finotello F, Hackl H, Hermann-Kleiter N, Löwer M, Baier G, Krogsdam A and Trajanoski Z: Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat Commun. 9:322018. View Article : Google Scholar : PubMed/NCBI
16	Tang XH, Knudsen B, Bemis D, Tickoo S and Gudas LJ: Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res. 10:301–313. 2004. View Article : Google Scholar : PubMed/NCBI
17	DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 43:491–498. 2011. View Article : Google Scholar : PubMed/NCBI
18	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA: The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Schumacher TN and Schreiber RD: Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
21	Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ and Stratton MR: Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3:246–259. 2013. View Article : Google Scholar : PubMed/NCBI
22	Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al: Signatures of mutational processes in human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
23	Sun S, Schiller JH and Gazdar AF: Lung cancer in never smokers-a different disease. Nat Rev Cancer. 7:778–790. 2007. View Article : Google Scholar : PubMed/NCBI
24	Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, Brennan P, Boffetta P, Zaridze DG and Hainaut P: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. Cancer Res. 65:5076–5083. 2005. View Article : Google Scholar : PubMed/NCBI
25	Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, et al: Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology. 146:401–411. 2014. View Article : Google Scholar
26	Tajima A, Hess MT, Cabrera BL, Kolodner RD and Carethers JM: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: Implications for chemosensitivity and resistance. Gastroenterology. 127:1678–1684. 2004. View Article : Google Scholar : PubMed/NCBI
27	Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA and Joensuu H: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemo-therapy. Gastroenterology. 119:921–928. 2000. View Article : Google Scholar : PubMed/NCBI
28	Baretti M and Le DT: DNA mismatch repair in cancer. Pharmacol Ther. 189:45–62. 2018. View Article : Google Scholar : PubMed/NCBI
29	Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al: Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. CELL. 167:397–404. 2016. View Article : Google Scholar
30	Hynes NE and Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
31	Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, et al: PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs. Cancer Res. 77:6365–6374. 2017. View Article : Google Scholar : PubMed/NCBI
32	Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, et al: Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 153:1107–1119. 2017. View Article : Google Scholar
33	Bi Y, Deng J, Murry DJ and An G: A whole-body physiologically based pharmacokinetic model of gefitinib in mice and scale-up to humans. AAPS J. 18:228–238. 2016. View Article : Google Scholar :
34	Wherry EJ and Kurachi M: Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
35	Topalian SL, Taube JM, Anders RA and Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016. View Article : Google Scholar : PubMed/NCBI
36	Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M and Escors D: PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med. 3:581–592. 2011. View Article : Google Scholar : PubMed/NCBI
37	Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 560:382–386. 2018. View Article : Google Scholar : PubMed/NCBI
38	Flies DB and Chen L: The new B7s: Playing a pivotal role in tumor immunity. J Immunother. 30:251–260. 2007. View Article : Google Scholar : PubMed/NCBI
39	Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH and Vermeer PD: Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis. Oncotarget. 7:24194–24207. 2016. View Article : Google Scholar : PubMed/NCBI
40	Stack EC, Wang C, Roman KA and Hoyt CC: Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 70:46–58. 2014. View Article : Google Scholar : PubMed/NCBI
41	Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, Urba WJ, Curti BD, Bifulco CB and Fox BA: Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 3:472015. View Article : Google Scholar : PubMed/NCBI
42	Feng Z, Jensen SM, Messenheimer DJ, Farhad M, Neuberger M, Bifulco CB and Fox BA: Multispectral imaging of T and B cells in murine spleen and tumor. J Immunol. 196:3943–3950. 2016. View Article : Google Scholar : PubMed/NCBI
43	Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH and Wang L: Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA. 112:6682–6687. 2015. View Article : Google Scholar : PubMed/NCBI